Literature DB >> 33382158

circBICD2 targets miR-149-5p/IGF2BP1 axis to regulate oral squamous cell carcinoma progression.

Lehong Qiu1, Linlin Zheng2, Chengwen Gan1, Wei Deng1, Ying Sun1, Tao Wang1.   

Abstract

BACKGROUND: Circular RNAs (circRNAs) are related to oral squamous cell carcinoma (OSCC) progression. circRNA bicaudal D cargo adaptor 2 (circBICD2) has been reported to be abnormally expressed in OSCC. However, the function and mechanism of this circRNA in OSCC progression remain largely unknown.
METHODS: circBICD2, microRNA-149-5p (miR-149-5p), and insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) abundances were examined via quantitative reverse transcription polymerase chain reaction or Western blot. The function of circBICD2 was investigated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), colony formation, flow cytometry, wound healing, transwell, specific kits, Western blot, and xenograft analyses. Dual-luciferase reporter analysis and RNA immunoprecipitation were carried out to analyze the binding interaction.
RESULTS: circBICD2 expression was enhanced in OSCC tissues and cells. circBICD2 silence suppressed OSCC cell proliferation, migration, invasion, and glutaminolysis and facilitated apoptosis. miR-149-5p was targeted via circBICD2 and decreased in OSCC tissues and cells. miR-149-5p knockdown attenuated silence of circBICD2 on the influence of OSCC cell proliferation, apoptosis, migration, invasion, and glutaminolysis. IGF2BP1 was targeted via miR-149-5p, and circBICD2 could regulate IGF2BP1 via miR-149-5p. IGF2BP1 interference constrained OSCC cell proliferation, migration, invasion, and glutaminolysis and promoted apoptosis. circBICD2 silence reduced OSCC cell growth in xenograft model.
CONCLUSION: circBICD2 knockdown repressed OSCC cell proliferation, migration, invasion, and glutaminolysis and increased apoptosis via modulating miR-149-5p/IGF2BP1 axis, which might act as a potential target for OSCC treatment.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  IGF2BP1; circBICD2; miR-149-5p; oral squamous cell carcinoma

Mesh:

Substances:

Year:  2021        PMID: 33382158     DOI: 10.1111/jop.13156

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  6 in total

1.  Editorial: "Non-Coding RNAs in Head and Neck Squamous Cell Carcinoma".

Authors:  Wei Cao; Qiang Shen; Ming Yann Lim
Journal:  Front Oncol       Date:  2021-12-23       Impact factor: 6.244

2.  Circular RNA mitochondrial translation optimization 1 homologue (CircMTO1) induced by zinc finger protein 460 (ZNF460) promotes oral squamous cell carcinoma progression through the microRNA miR-320a / alpha thalassemia/mental retardation, X-linked (ATRX) axis.

Authors:  Chen Zou; Xia Li; Xiaozhi Lv; Siyuan Wu; Jing Song; Zhe Tang; Hailing Luo; Haigang Wei; Yilong Ai
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

3.  The Circular RNA CircCOL1A1 Functions as a miR-149-5p Sponge to Regulate the Formation of Superior-Quality Brush Hair via the CMTM3/AR Axis.

Authors:  Jian Wang; Xi Wu; Xiaomei Sun; Liuming Zhang; Qiang Wang; Jingwen Qu; Yanhu Wang; Yongjun Li
Journal:  Front Cell Dev Biol       Date:  2022-02-02

Review 4.  Role of IGF2BPs in head and neck squamous cell carcinoma.

Authors:  Kainan Wu; Fen Chang; Wenming Li; Tongdong Su; Dapeng Lei
Journal:  Front Oncol       Date:  2022-09-27       Impact factor: 5.738

Review 5.  Tumor-Suppressive and Oncogenic Roles of microRNA-149-5p in Human Cancers.

Authors:  Yang Shen; Nan Zhao; Nan Zhao; Xinyao Hu; Xiaoqin He; Yangtao Xu; Jiayu Chen; Wenliang Chen; Xin Liu; Zhuolin Zhou; Dedong Cao; Ximing Xu
Journal:  Int J Mol Sci       Date:  2022-09-16       Impact factor: 6.208

6.  CircRNA HIPK3 promotes the progression of oral squamous cell carcinoma through upregulation of the NUPR1/PI3K/AKT pathway by sponging miR-637.

Authors:  Weipeng Jiang; Chunxiao Zhang; Xiaoming Zhang; Legang Sun; Jikui Li; Jinhua Zuo
Journal:  Ann Transl Med       Date:  2021-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.